Physician profile
Heather Vaught
NPI 1235608951
$5,516.06
in general payments reported to CMS, 2019-2025
23 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,157 · 2020: $165 · 2021: $547 · 2022: $383 · 2023: $539 · 2024: $1,164 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Entertainment: $249.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,014.67 |
| Entertainment | $249.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $1,017.91 | 2019 | |
| Coopervision INC. | $721.33 | 2019-2024 | Myday Contact Lens |
| Bausch & Lomb Americas INC. | $535.63 | 2023-2025 | Miebo, Xiidra, Infuse |
| Lkc Technologies, INC. | $498.93 | 2024-2025 | |
| Optos, INC. | $487.64 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sight Sciences, INC. | $405.96 | 2022-2025 | Tearcare System, Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $241.88 | 2021 | |
| Abbvie INC. | $221.83 | 2022-2025 | Durysta, Vuity, Alphagan P |
| Horizon Therapeutics Plc | $203.43 | 2022-2023 | Tepezza |
| Oyster Point Pharma, INC. | $202.09 | 2022-2025 | Tyrvaya, Ryzumvi |
| Biotissue Holdings INC. | $184.49 | 2024-2025 | |
| Notal Vision, INC. | $146.51 | 2024 | Foresee Home |
| Tarsus Pharmaceuticals, INC. | $143.19 | 2025 | Xdemvy |
| Astellas Pharma US INC | $123.98 | 2025 | Izervay |
| Amgen INC. | $103.43 | 2024 | Tepezza |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $73.53 | 2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $69.93 | 2022-2025 | |
| Carl Zeiss Meditec USA, INC. | $37.32 | 2025 | Atlas Corneal Topography System |
| Kala Pharmaceuticals, INC. | $23.46 | 2021 | |
| Alcon Vision LLC | $21.78 | 2025 | Tryptyr |
| Harrow Eye, LLC | $20.43 | 2025 | Vevye |
| Allergan, INC. | $18.48 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Vaught listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.